Screener
Vor Biopharma VOR CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities | ||
| Purchases of marketable securities | (276,500) | — |
| Proceeds from maturities of marketable securities | 13,311 | 1 |
| Purchases of property and equipment | (48) | (231) |
| Net cash used in investing activities | (263,237) | (230) |
| Cash flows from financing activities | ||
| Payment of issuance costs related to private placement | (127) | (551) |
| Repurchases of shares for tax withholdings upon vesting of restricted stock unit awards | (2) | (55) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's capex?
- Vor Biopharma (VOR) reported capex of $48K in Q1 2026.
- How has Vor Biopharma's capex changed year-over-year?
- Vor Biopharma's capex decreased by 79.2% year-over-year, from $231K to $48K.
- What is the long-term trend for Vor Biopharma's capex?
- Over 4 years (2021 to 2025), Vor Biopharma's capex has grown at a -29.9% compound annual growth rate (CAGR), from $3.89M to $941K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Vor Biopharma's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude